{
    "clinical_study": {
        "@rank": "137949", 
        "acronym": "LEVO-PHARM", 
        "arm_group": {
            "arm_group_label": "Levofloxacin", 
            "arm_group_type": "Experimental", 
            "description": "Population having a community-acquired pneumonia of wich the indication of the treatment is administration of Levofloxacin"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is 1. to describe levofloxacin pharmacokinetics in ICU patients\n      suffering from pneumonia with taking into account physio-pathological parameters. 2. to\n      verify clinical and bacteriological efficiency and to know if the peak/Minimum Inhibitory\n      Concentration (MIC) ratio > 5 and Area Under Curve (AUC) /Minimum Inhibitory\n      Concentration(MIC) ratio > 125. No therapeutic drug monitoring will be performed in this\n      study."
        }, 
        "brief_title": "Pharmacokinetics of Levofloxacin in Intensive Care Unit", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Intensive Care Unit Syndrome", 
            "Community-acquired Pneumonia"
        ], 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  severe community-acquired pneumonia due to a strain sensible to levofloxacin\n\n          -  Age > 18 years\n\n          -  Informed consent\n\n          -  SAPS II (simplified acute physiological score) > 20 Awaited duration of survival\n             higher than 7 days\n\n        Exclusion Criteria:\n\n          -  Historic of allergy to levofloxacin\n\n          -  Resistant strain to levofloxacin\n\n          -  Pregnancy\n\n          -  Contra-indications of levofloxacin use, renal failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018081", 
            "org_study_id": "10 150 02"
        }, 
        "intervention": {
            "arm_group_label": "Levofloxacin", 
            "description": "8 blood sampling by patients between the 48th and 60th", 
            "intervention_name": "Levofloxacin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ofloxacin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "pharmacokinetic study : open, prospective, monocentric", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "georges.b@chu-toulouse.fr", 
                "last_name": "Bernard GEORGES, MD, PhD", 
                "phone": "05 61 32 23 41", 
                "phone_ext": "33"
            }, 
            "contact_backup": {
                "email": "conil.jm@chu-toulouse.fr", 
                "last_name": "Jean-Marie CONIL, MD, PhD", 
                "phone": "05 61 32 24 86", 
                "phone_ext": "33"
            }, 
            "facility": {
                "address": {
                    "city": "Toulouse", 
                    "country": "France", 
                    "zip": "31059"
                }, 
                "name": "University Hospital Toulouse"
            }, 
            "investigator": [
                {
                    "last_name": "Mich\u00e8le GENESTAL, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "B\u00e9atrice RIU, Md, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Pierre COUGOT, Md, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "St\u00e9phanie RUIZ, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jean-Fran\u00e7ois DECUN, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Population Pharmacokinetics of Levofloxacin in Intensive Care Patients With Severe Community-acquired Pneumonia.", 
        "overall_contact": {
            "email": "georges.b@chu-toulouse.fr", 
            "last_name": "Bernard GEORGES, MD, PhD", 
            "phone": "05 61 32 23 41", 
            "phone_ext": "33"
        }, 
        "overall_contact_backup": {
            "email": "conil.jm@chu-toulouse.fr", 
            "last_name": "Jean-Marie CONIL, MD, PhD", 
            "phone": "05 61 32 24 86", 
            "phone_ext": "33"
        }, 
        "overall_official": {
            "affiliation": "University Hospital of Toulouse", 
            "last_name": "Bernard GEORGES, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Levofloxacin dosage regimen, time of administration and time of blood sampling, levofloxacin serum concentrations.", 
            "safety_issue": "Yes", 
            "time_frame": "Levofloxacin concentration assessment at  8 different  time points during 12h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018081"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "age, weight, height, sex, SAPS II, blood urea nitrogen (BUN), creatinine, mechanical ventilation, leukocytes, haemoglobin, procalcitonin, creatinine clearance, proteins, MIC of the strain.", 
            "measure": "Efficiency (clinical,bacteriological, pharmacodynamic)", 
            "safety_issue": "Yes", 
            "time_frame": "12 hours"
        }, 
        "source": "University Hospital, Toulouse", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Toulouse", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}